Scarica l'app Stockscreener
14.71
1.34%
-0.20
Precedente Chiudi:
$14.91
Aprire:
$15.22
Volume 24 ore:
1.24M
Relative Volume:
0.67
Capitalizzazione di mercato:
$1.18B
Reddito:
-
Utile/perdita netta:
$-149.96M
Rapporto P/E:
-8.1185
EPS:
-1.8119
Flusso di cassa netto:
$-134.67M
1 W Prestazione:
-31.74%
1M Prestazione:
-34.88%
6M Prestazione:
+89.32%
1 anno Prestazione:
+236.61%
Intervallo 1D:
$14.36
$15.50
Intervallo di 1 settimana:
$12.99
$18.62
Portata 52W:
$2.86
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Nome
Olema Pharmaceuticals Inc
Settore
Industria
Telefono
(415) 651-3316
Indirizzo
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
14.71 | 1.18B | 0 | -149.96M | -134.67M | -1.8119 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-11 | Iniziato | Stifel | Buy |
| 2026-01-07 | Iniziato | Piper Sandler | Overweight |
| 2025-10-08 | Iniziato | Guggenheim | Buy |
| 2025-08-12 | Reiterato | Citigroup | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2024-01-30 | Iniziato | Citigroup | Buy |
| 2023-07-21 | Iniziato | Oppenheimer | Outperform |
| 2023-05-05 | Iniziato | CapitalOne | Overweight |
| 2023-02-22 | Iniziato | Credit Suisse | Outperform |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Iniziato | H.C. Wainwright | Neutral |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2020-12-14 | Iniziato | Canaccord Genuity | Buy |
| 2020-12-14 | Iniziato | Cowen | Outperform |
| 2020-12-14 | Iniziato | JP Morgan | Overweight |
| 2020-12-14 | Iniziato | Jefferies | Buy |
Mostra tutto
Olema Pharmaceuticals Inc Borsa (OLMA) Ultime notizie
Pier Capital LLC Has $5.13 Million Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Assessing Olema Pharmaceuticals (OLMA) Valuation After Breast Cancer Trial Setback Hits Sector Sentiment - Sahm
HC Wainwright Has Negative Forecast for OLMA FY2029 Earnings - MarketBeat
Momentum Shift: Will Olema Pharmaceuticals Inc outperform its industry peersMarket Trend Review & Weekly Top Gainers Trade List - baoquankhu1.vn
Insider sales at OLMA (NASDAQ: OLMA) include 241,999-share block in March - Stock Titan
What's Going On With Olema Pharmaceuticals Stock On Wednesday? - Benzinga
Does Olema Pharmaceuticals (OLMA) Still Stand Apart After Roche’s Breast Cancer Trial Setback? - Sahm
H.C. Wainwright does not see direct read from Roche miss to Olema’s OPERA-02 - Yahoo Finance
Olema Pharmaceuticals (OLMA) to Release Quarterly Earnings on Tuesday - MarketBeat
Oppenheimer, Cowen, H.C. Wainwright Maintain Buy/Outperform on OLMA March 2026 - Meyka
Olema Pharmaceuticals (OLMA) Maintains Buy Rating Despite Lowered Price Target | OLMA Stock News - GuruFocus
Olema Pharmaceuticals (OLMA) Stock Plummets 41% on Roche Trial Disappointment - MEXC
OLMA (OLMA) Form 144: Affiliate sales, officer sold 190,343 shares - Stock Titan
H.C. Wainwright cuts Olema Pharmaceuticals price target on trial data By Investing.com - Investing.com Canada
Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Benzinga
Stifel reiterates Buy on Olema stock after Roche trial miss By Investing.com - Investing.com Canada
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down Following Analyst Downgrade - MarketBeat
HC Wainwright Cuts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $38.00 - MarketBeat
TD Cowen reiterates Olema Pharmaceuticals stock rating on trial outlook By Investing.com - Investing.com Canada
Why Is Olema Pharmaceuticals Stock Dropping On Monday?Olema Pharmaceuticals (NASDAQ:OLMA) - Benzinga
Olema Pharmaceuticals Faces Strategic Shifts Amid Market Turbulence - StocksToTrade
Oppenheimer reiterates Olema Pharmaceuticals stock rating at Outperform By Investing.com - Investing.com Canada
Olema Pharmaceuticals (OLMA) Stock Crashes After Roche Breast Cancer Trial Fails - CoinCentral
Olema Pharmaceuticals stock tumbles 41% on Roche trial data By Investing.com - Investing.com Canada
Olema earnings loom as analysts eye palazestrant potential - Investing.com Australia
Institution Moves: Is Olema Pharmaceuticals Inc stock trending bullish2025 Short Interest & Weekly Breakout Watchlists - baoquankhu1.vn
FMR LLC holds 12.5% of OLEMA (NASDAQ: OLMA) common stock - Stock Titan
Shawnte Mitchell Sells 15,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Insider Shawnte Mitchell Sells 25,000 Shares - MarketBeat
Olema Pharmaceuticals (NASDAQ: OLMA) CLO nets 40,000-share stock sale - Stock Titan
Aug Intraday: Is Olema Pharmaceuticals Inc backed by strong institutional buyingPortfolio Value Report & Smart Money Movement Alerts - baoquankhu1.vn
Olma Health (NASDAQ: OLMA) director reports several stock sales in Jan–Feb 2026 - Stock Titan
Insider sells 15,000 OLMA shares; 25,000-share option sale planned (OLMA) - Stock Titan
OLMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Olema Pharmaceuticals Grants Stock Options to New Employees Under 2022 Inducement Plan - Quiver Quantitative
[144] Olema Pharmaceuticals, Inc. SEC Filing - Stock Titan
How Leadership Turnover and Palazestrant Optimism At Olema Pharmaceuticals (OLMA) Has Changed Its Investment Story - Sahm
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Olema Pharmaceuticals CEO to join TDCowen Health Care Conference fireside chat in Boston - Traders Union
Olema Pharmaceuticals CEO Touts Palazestrant Edge as Oral SERDs Shake Out at Conference - MarketBeat
How Leadership Turnover During Key Trial Milestones Will Impact Olema Pharmaceuticals (OLMA) Investors - Yahoo Finance
Olema Pharmaceuticals (OLMA) Valuation Check After Recent Share Price Volatility - simplywall.st
OLMA Should I Buy - Intellectia AI
Citi, Stifel Bullish on Olema (OLMA) Despite COO Departure - Yahoo Finance
Olema earnings on deck: Biotech faces widening loss ahead of key data By Investing.com - Investing.com South Africa
Olema earnings on deck: Biotech faces widening loss ahead of key data - Investing.com Australia
Olema Pharmaceuticals, Inc. (OLMA): Investor Outlook on a Promising Biotech with 91% Potential Upside - DirectorsTalk Interviews
20,000-share Form 144 filed for Olami Medical (NASDAQ: OLMA) - Stock Titan
Olema Pharmaceuticals CEO Spotlights Phase 3 Palazestrant Trials, KAT6 Program at Citi Summit - MarketBeat
Shane Kovacs sells 110,000 OLMA shares across Jan–Feb 2026 (NASDAQ: OLMA) - Stock Titan
Olema Pharmaceuticals Inc Azioni (OLMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):